{
    "clinical_study": {
        "@rank": "80498", 
        "arm_group": [
            {
                "arm_group_label": "AZD3293", 
                "arm_group_type": "Experimental", 
                "description": "Up to 11 sequential cohorts of healthy young and healthy elderly subjects are planned, with single ascending doses ranging from 1mg to a maximum of 1000mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given (2 subjects in each cohort)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single dose study in healthy male and female (of non-child bearing potential)\n      volunteers, to assess the safety, effects on the body, and blood and urine drug levels of\n      AZD3293.  AZD3293 is being developed for the treatment of Alzheimer's Disease"
        }, 
        "brief_title": "A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Young Volunteers", 
            "Healthy Elderly Volunteers"
        ], 
        "detailed_description": {
            "textblock": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to\n      Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293\n      Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female (of non-childbearing potential) subjects\n\n          -  Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more\n             than 100 kg\n\n        Exclusion Criteria:\n\n          -  History or presence of psychiatric disease/condition, GI, renal, hepatic,\n             cardiovascular, psychiatric, or retinal diseases or disorders\n\n          -  History of neurological disease, including seizures, recent memory impairment, or\n             clinically significant head injury\n\n          -  History of use of antipsychotic drugs , or chronic use of antidepressant or\n             anxiolytic drugs\n\n          -  Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other\n             nicotine products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739647", 
            "org_study_id": "D5010C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "AZD3293", 
                "description": "Oral solution", 
                "intervention_name": "AZD3293", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Oral solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "AZD3293", 
            "Healthy volunteers", 
            "Elderly volunteers", 
            "Phase 1", 
            "Single Ascending Dose Study"
        ], 
        "lastchanged_date": "August 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Robert C Alexander, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "PAREXEL Early Phase Clinical Unit", 
                "last_name": "Ronald Goldwater, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Adverse event monitoring.", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline up to 10 days."
            }, 
            {
                "description": "The vital signs of body temperature, blood pressure and pulse are going to be measured.", 
                "measure": "Assessment of vital signs and physical examination.", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline up to 10 days."
            }, 
            {
                "measure": "Clinical laboratory tests: hematology.", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline up to 10 days."
            }, 
            {
                "measure": "Clinical laboratory tests: urine analysis.", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline up to 10 days."
            }, 
            {
                "description": "QT/QTc interval, rhythm, rate, morphology is going to be measured.", 
                "measure": "Evaluation of 12-lead digital electrocardiogram (ECG).", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline up to 10 days."
            }, 
            {
                "description": "As reported by investigator.", 
                "measure": "Assessment of telemetry.", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline up to 10 days."
            }, 
            {
                "description": "Columbia-Suicide Severity Rating Scale (C-SSRS) captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. Some questions are yes/no and some are on a scale of 1 (low severity) to 5 (high severity). Completed suicide and non-fatal suicide events are yes/no questions and results presented are the number of participants with these events. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.", 
                "measure": "Columbia-Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline up to 10 days."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Where (AUC(0-t)) is area under the plasma concentration-time curve from zero to the last measurable concentration and (AUC(0-24)) area under the plasma concentration-time curve from zero to 24 hours post-dose.", 
                "measure": "Pharmacokinetics (PK) in the terms of AUC, AUC(0-t), AUC(0-24).", 
                "safety_issue": "No", 
                "time_frame": "Up 4 days"
            }, 
            {
                "description": "Biomarker PD A\u03b2 (1-40, 1-42) parameters are:\nMaximum observed plasma concentration (Cmax)\nTime to Cmax (tmax)\nMinimum observed plasma concentration (Cmin)\nMinimum observed plasma concentration below the individual healthy volunteer baseline (pre-dose biomarker concentration prior to dosing) (\u0394Cmin)\nTime to Cmin (tmin)\nDuration (T) of concentration below individual healthy volunteer baseline (BBL), if appropriate for the data (tBBL)\nArea under the plasma concentration-time curve from zero to the time of the last quantifiable concentration (AUC(0-t))\nArea under the plasma concentration-time curve from zero to 24 hours post dose (AUC(0-24))\nArea under the plasma biomarker concentration curve from time zero to 24 hour that is below individual healthy volunteer baseline (\u0394AUC(0-24)).", 
                "measure": "Investigation on the effect of AZD3293 on biomarkers relevant for Pharmacodynamics in plasma.", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 days."
            }, 
            {
                "description": "Pharmacokinetics (PK) in the terms of plasma Cmax and AUC.", 
                "measure": "Investigation of the potential influence of food on Pharmacokinetics (PK)  following a single dose of AZD3293.", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 days."
            }, 
            {
                "description": "The Pharmacokinetics (PK) variables may be plasma concentrations or summary measurements such as Cmax or AUC.  The Pharmacodynamics (PD) variables may include biomarkers in plasma such as A\u03b2 (1-40, 1-42) or exploratory PD biomarkers, or safety variables.", 
                "measure": "Investigation of the relationship between Pharmacokinetics (PK) and Pharmacodynamics (PD) of AZD3293.", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 days."
            }, 
            {
                "measure": "Pharmacokinetics assessment in the terms of fu (%) (fraction of unbound AZD3293 and AZ13569724 in plasma).", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 days."
            }, 
            {
                "measure": "Pharmacokinetics in the terms of Cmax (Maximum observed plasma concentration) and tmax  (Time to Cmax ).", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 days."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}